By Chris Wack
Autonomix Medical shares were up 24% to $4.10 after the company said it received a patent from the U.S. Patent and Trademark Office.
The medical device company said the patent, titled Systems and Methods for Treating Cancer and/or Augmenting Organ Function, covers technology including systems, methods and devices for interventionalply treating cancerous tumors and cancer-related pain.
The Woodlands, Texas, company said it is developing its technology to initially focus on pancreatic cancer pain relief.
A previous preclinical study showed the company's nerve ablation technique significantly reduced metastases and tumor mass in mice, highlighting the role of neural pathways in pancreatic cancer.
Autonomix said it is currently conducting a human clinical trial aimed at pain reduction via nerve ablation near the pancreas, with future studies planned to validate these preclinical results in clinical settings.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 30, 2024 13:37 ET (18:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。